Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1166 ARTÍCULOS , VIENDO DEL 961 AL 975

Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology

Arendt T, Stieler J, Holzer M.

J Neural Transm (Vienna). 2015 Apr;122(4):531-9. doi: 10.1007/s00702-014-1342-8. Epub 2014 Dec 6.

Pharmacotherapy of Alzheimer's disease: current and future trends

Geldenhuys WJ, Darvesh AS.

Expert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884. Epub 2014 Dec 8.

Tau aggregation and its interplay with amyloid-β

Nisbet RM, Polanco JC, Ittner LM, Götz J.

Acta Neuropathol. 2015 Feb;129(2):207-20. doi: 10.1007/s00401-014-1371-2. Epub 2014 Dec 10.

Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets

Prakash A, Kalra J, Mani V, Ramasamy K, Majeed AB.

Expert Rev Neurother. 2015 Jan;15(1):53-71. doi: 10.1586/14737175.2015.988709. Epub 2014 Dec 12.

Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication

Deardorff WJ, Shobassy A, Grossberg GT.

Expert Rev Neurother. 2015 Jan;15(1):7-17. doi: 10.1586/14737175.2015.995639. Epub 2014 Dec 15.

An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer's disease and neurodegeneration

Pike AF, Kramer NI, Blaauboer BJ, Seinen W, Brands R.

Chem Biol Interact. 2015 Jan 25;226:30-9. doi: 10.1016/j.cbi.2014.12.006. Epub 2014 Dec 11.

Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment

Lombardo S, Maskos U.

Neuropharmacology. 2015 Sep;96(Pt B):255-62. doi: 10.1016/j.neuropharm.2014.11.018. Epub 2014 Dec 13.

Commentary: is Alzheimer's disease uniquely human?

Finch CE, Austad SN.

Neurobiol Aging. 2015 Feb;36(2):553-5. doi: 10.1016/j.neurobiolaging.2014.10.025. Epub 2014 Oct 23.

Neuropathology and biochemistry of Aβ and its aggregates in Alzheimer's disease

Thal DR, Walter J, Saido TC, Fändrich M.

Acta Neuropathol. 2015 Feb;129(2):167-82. doi: 10.1007/s00401-014-1375-y. Epub 2014 Dec 23.

The neural correlates of road sign knowledge and route learning in semantic dementia and Alzheimer's disease

Luzzi S, Cafazzo V, Damora A, Fabi K, Fringuelli FM, Ascoli G, Silvestrini M, Provinciali L, Reverberi C.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):595-602. doi: 10.1136/jnnp-2014-309477. Epub 2014 Dec 22.

Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future

Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S.

Expert Rev Neurother. 2015 Jan;15(1):83-105. doi: 10.1586/14737175.2015.995637. Epub 2014 Dec 24.

Charting a path toward combination therapy for Alzheimer's disease

Stephenson D, Perry D, Bens C, Bain LJ, Berry D, Krams M, Sperling R, Dilts D, Luthman J, Hanna D, McKew J, Temple R, Fields FO, Salloway S, Katz R.

Expert Rev Neurother. 2015 Jan;15(1):107-13. doi: 10.1586/14737175.2015.995168. Epub 2014 Dec 26.

Golgi defects enhance APP amyloidogenic processing in Alzheimer's disease

Joshi G, Wang Y.

Bioessays. 2015 Mar;37(3):240-7. doi: 10.1002/bies.201400116. Epub 2014 Dec 28.

Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials

Jiang D, Yang X, Li M, Wang Y, Wang Y.

J Neural Transm (Vienna). 2015 Aug;122(8):1157-66. doi: 10.1007/s00702-014-1358-0. Epub 2014 Dec 30.

ER stress signaling and neurodegeneration: At the intersection between Alzheimer's disease and Prion-related disorders

Torres M, Matamala JM, Duran-Aniotz C, Cornejo VH, Foley A, Hetz C.

Virus Res. 2015 Sep 2;207:69-75. doi: 10.1016/j.virusres.2014.12.018. Epub 2014 Dec 31.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias